Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)



Status:Completed
Conditions:Ocular, Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:12/21/2018
Start Date:August 29, 2011
End Date:April 28, 2012

Use our guide to learn which trials are right for you!

A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)

The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%)
compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118
Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID
for 12 weeks will also be evaluated.


Inclusion Criteria:

- Willing and able to read, sign, and date the informed consent and HIPAA documents

- Willing and able to comply with all study procedures

- Be at least 18 years of age

- Patient-reported history of dry eye in both eyes

- Demonstrate a positive response when exposed to the Controlled Adverse Environment
model

- A negative urine pregnancy test if female of childbearing potential and must use
adequate birth control throughout the study period

Exclusion Criteria:

- Any ocular condition that, in the opinion of the Investigator, could affect study
parameters including, but not limited to, active ocular infection, ocular
inflammation, glaucoma, and/or diabetic retinopathy

- Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the
study period

- Any blood donation or significant loss of blood within 56 days of Visit 1

- Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.

- Use of any topical ophthalmic preparations (including artificial tear substitutes) 72
hrs prior to Visit 1 and during the study

- Any significant chronic illness that could interfere with study parameters

- History of laser‑assisted in situ keratomileusis (LASIK) or similar type of corneal
refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical
procedure within 12 months prior to Visit 1; or any scheduled ocular surgical
procedure during the study period.

- Known history of alcohol and/or drug abuse

- Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet
cells (as with Vitamin A deficiency)
We found this trial at
13
sites
Winchester, Massachusetts 01890
?
mi
from
Winchester, MA
Click here to add this to my saved trials
Andover, Massachusetts 01840
?
mi
from
Andover, MA
Click here to add this to my saved trials
Augusta, Maine 04330
?
mi
from
Augusta, ME
Click here to add this to my saved trials
Derry, New Hampshire 03038
?
mi
from
Derry, NH
Click here to add this to my saved trials
Lancaster, Massachusetts 01523
?
mi
from
Lancaster, MA
Click here to add this to my saved trials
Lewiston, Maine 04243
?
mi
from
Lewiston, ME
Click here to add this to my saved trials
Louisville, Kentucky 40405
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Manchester, New Hampshire 03101
?
mi
from
Manchester, NH
Click here to add this to my saved trials
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Norfolk, Virginia 23502
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Quincy, Massachusetts 02169
?
mi
from
Quincy, MA
Click here to add this to my saved trials
Wakefield, Massachusetts 01880
?
mi
from
Wakefield, MA
Click here to add this to my saved trials
Waterbury, Connecticut 06708
?
mi
from
Waterbury, CT
Click here to add this to my saved trials